Metabolic

Survodutide Dosage Protocol

A GLP-1/glucagon dual agonist in Phase 3 trials for obesity and NASH/MASH with significant liver histology improvement. Complete titration schedule and peer-reviewed references.

Last reviewed March 2025 · 1 cited source

Reconstitution

Add 2.0 mL BAC water → 5 mg/mL

Daily dose range

0.6–6 mg weekly (titrated)

Unit math (U-100 syringe)

1 unit = 0.01 mL ≈ 50 mcg

Storage (lyophilized)

Freeze at −4 °F · Reconstituted: 36–46 °F · Use within 28 days

Dosing & Reconstitution Guide

The protocol below uses a 2.0 mL reconstitution volume to keep injection units comfortably above 10 on a standard U-100 insulin syringe, reducing measurement error. Doses are titrated as shown below.

Phase	Daily dose	U-100 units	Injection volume
Weeks 1–4	0.6 mg	12 units	0.12 mL
Weeks 5–8	1.2 mg	24 units	0.24 mL
Weeks 9–12	2.4 mg	48 units	0.48 mL
Maintenance	4.8–6 mg	96–120 units	0.96–1.20 mL

Route: Subcutaneous · Frequency: Once WEEKLY SC · Cycle: 20+ weeks

Reconstitution steps

Draw 2.0 mL of bacteriostatic water into a sterile syringe.

Inject the water slowly down the interior wall of the peptide vial -never directly onto the powder -to prevent foaming and denaturation.

Swirl or roll gently until fully dissolved. Do not shake. The lyophilized powder should dissolve completely within 30–60 seconds.

Label the vial with the reconstitution date and concentration (5 mg/mL). Refrigerate at 36–46 °F, protected from light. Use within 28 days.

Research use only. This protocol is derived from published preclinical and early-phase clinical literature. Survodutide is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.

Supplies Needed

Estimates below assume the titration schedule listed above.

Survodutide vials (10 mg each)

Per cycleAs needed per titration

U-100 insulin syringes

8 weeks56 syringes

12 weeks84 syringes

16 weeks112 syringes

Bacteriostatic water (10 mL bottles)

Per vial2.0 mL needed

Alcohol swabs (100-count boxes)

8 weeks2 boxes (~112 swabs)

12 weeks2 boxes (~168 swabs)

16 weeks3 boxes (~224 swabs)

Storage Instructions

Lyophilized (dry powder)

−4 °F

Store frozen in dry, dark conditions. Minimize humidity exposure. Stable for 12–24 months when properly stored.

Reconstituted (in solution)

36–46 °F

Refrigerate after reconstitution. Use within 28 days. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.

Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.

Verified Source

Looking for research-grade peptides? Pacific Edge Labs carries a growing catalog of high-purity compounds with third-party lab results published on each product page.

Why Pacific Edge Labs

High-purity compounds with third-party lab results available on the website
Consistent quality control with ISO-aligned handling and documentation
Fast, discreet shipping with proper handling and packaging

Browse Pacific Edge Labs →

Survodutide is not currently in the PEL catalog -check back for availability.

How Survodutide Works

Survodutide (BI 456906) is a dual receptor agonist targeting GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression and glycemic control, while glucagon receptor agonism promotes thermogenesis and hepatic lipid oxidation -effects particularly relevant for non-alcoholic steatohepatitis (NASH/MASH) where liver fat accumulation drives disease progression.^[1]

Phase 2 trials demonstrated approximately 15% body weight reduction at 46 weeks for obesity and, notably, significant improvement in liver histology and fibrosis scores in NASH patients -a population with very limited treatment options. Phase 3 programs (SYNCHRONIZE for obesity, additional for NASH) are ongoing.^[2]

Observed Effects & Side Effect Profile

The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.

Reported benefits (research literature)

~15% body weight reduction in Phase 2 obesity trial
Significant liver histology and fibrosis improvement in Phase 2 NASH trial
Dual mechanism addresses both metabolic and hepatic pathology
Once-weekly dosing convenience

Known limitations & side effects

Gastrointestinal effects (nausea, vomiting, diarrhea) during dose escalation
Slow titration required over many weeks
Phase 3 ongoing -not yet FDA-approved
Glucagon component may transiently elevate blood glucose
Long-term cardiovascular safety data not yet available

Lifestyle Considerations

While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:

Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.

Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.

Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.

Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.

Injection Technique

Standard subcutaneous injection guidance from clinical best-practice references.

Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.

Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.

Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.

Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.

Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.

Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.

Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.

Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.

Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.

Important Notes

⚠

Research use only. Survodutide is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.

◎

One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.

◎

Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.

◎

Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.

References

All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.

PubMed 38330987

Blüher M et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

pubmed.ncbi.nlm.nih.gov/38330987 ↗